Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors

被引：0
作者：
Noritoshi, K. [1 ]
Sho, H. [1 ]
Wild, D. [2 ]
Kaul, F. [2 ]
Motokazu, S. [1 ]
Naoki, O. [1 ]
Risa, F. [1 ]
Akihiro, S. [1 ]
Motohiko, T. [1 ]
Shoko, T. [1 ]
Yasushi, I [1 ]
机构：
[1] Yokohama City Univ, Yokohama, Kanagawa, Japan
[2] Univ Hosp Basel, Basel, Switzerland
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷
关键词：
lesion-based analysis; neuroendocrine tumor; peptide receptor radionuclide therapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H29
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
    Kaemmerer, Daniel
    Prasad, Vikas
    Daffner, Wolfgang
    Hoersch, Dieter
    Kloeppel, Guenter
    Hommann, Merten
    Baum, Richard P.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (46) : 5867 - 5870
  • [22] Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors
    Almeamar, H.
    Cullen, L.
    Murphy, D.
    Crowley, R.
    Skehan, S.
    Welin, S.
    O'Shea, D.
    O'Toole, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 136 - 136
  • [23] Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
    Starr, Jason S.
    Sonbol, Mohamad Bassam
    Hobday, Timothy J.
    Sharma, Akash
    Kendi, Ayse Tuba
    Halfdanarson, Thorvardur R.
    ONCOTARGETS AND THERAPY, 2020, 13 : 3545 - 3555
  • [24] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Marco Schiavo Lena
    Stefano Partelli
    Paola Castelli
    Valentina Andreasi
    Chanel Elisha Smart
    Eleonora Pisa
    Mirco Bartolomei
    Emilio Bertani
    Giuseppe Zamboni
    Massimo Falconi
    Claudio Doglioni
    Endocrine Pathology, 2020, 31 : 119 - 131
  • [25] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Schiavo Lena, Marco
    Partelli, Stefano
    Castelli, Paola
    Andreasi, Valentina
    Smart, Chanel Elisha
    Pisa, Eleonora
    Bartolomei, Mirco
    Bertani, Emilio
    Zamboni, Giuseppe
    Falconi, Massimo
    Doglioni, Claudio
    ENDOCRINE PATHOLOGY, 2020, 31 (02) : 119 - 131
  • [26] Somatostatin receptor radionuclide therapy in neuroendocrine tumors
    Haider, Mintallah
    Das, Satya
    Al-Toubah, Taymeyah
    Pelle, Eleonora
    El-Haddad, Ghassan
    Strosberg, Jonathan
    ENDOCRINE-RELATED CANCER, 2021, 28 (03) : R81 - R93
  • [27] Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy
    Lehrman, Evan D.
    Fidelman, Nicholas
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2020, 37 (05) : 499 - 507
  • [28] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [29] Partial Response Upon Peptide Receptor Radionuclide Therapy in a Highly Proliferative Pancreatic Neuroendocrine Tumor
    Weich, Alexander
    Serfling, Sebastian E.
    Rowe, Steven P.
    Solnes, Lilja B.
    Buck, Andreas K.
    Higuchi, Takahiro
    Werner, Rudolf A.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (06) : 547 - 548
  • [30] Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
    Paolo Zanotti-Fregonara
    Clément Morgat
    Christophe Champion
    Elif Hindié
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1095 - 1096
12345